The 24 most recent market catalysts affecting $BMRN, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 15, 2026
Corporate Catalyst
Bearish
Impact 75
BioMarin Pharmaceutical shares are trading lower after the company announced its decision to discontinue development of VOXZOGO for children with Noonan syndrome.
The discontinuation of VOXZOGO development for Noonan syndrome is a significant negative event for BioMarin Pharmaceutical. While VOXZOGO is approved for achondroplasia, expanding …
Sep 15, 2026
Corporate Catalyst
Neutral
Impact 65
BioMarin Pharmaceutical Decides To Discontinue Development Of VOXZOGO For Children With Noonan Syndrome
BioMarin Pharmaceutical has decided to discontinue the development of VOXZOGO for children with Noonan syndrome. This matters because while VOXZOGO is already approved for achondro…
Sep 9, 2026
Corporate Catalyst
Bullish
Impact 85
BioMarin Says Phase 3 Study Of VOXZOGO In Hypochondroplasia Met Primary Endpoint With 2.33 cm/Year Improvement In Annualized Growth Velocity vs. Placebo At 52 Weeks; Says sNDA Submitted To FDA
This headline represents a significant corporate catalyst for BioMarin. The successful Phase 3 trial of VOXZOGO in hypochondroplasia, demonstrating a statistically significant impr…
Sep 1, 2026
Corporate Catalyst
Bullish
Impact 55
Piper Sandler Maintains Overweight on BioMarin Pharmaceutical, Raises Price Target to $90
Piper Sandler analyst Allison Bratzel maintained an 'Overweight' rating on BioMarin Pharmaceutical (BMRN) and raised the price target from $88 to $90. This action signals continued…
Aug 31, 2026
Corporate Catalyst
Bullish
Impact 55
Jefferies Maintains Buy on BioMarin Pharmaceutical, Raises Price Target to $105
Jefferies analyst Akash Tewari maintained a 'Buy' rating on BioMarin Pharmaceutical (BMRN) and raised the price target by a single dollar, from $104 to $105. This action signals on…
Aug 31, 2026
Corporate Catalyst
Bullish
Impact 75
Biomarin, Ascendis Reach Mutually Beneficial Agreement Ending Global Patent Disputes
BioMarin and Ascendis Pharma have ended their global patent disputes over Yuviwel, a key drug for achondroplasia. This settlement is significant because it provides BioMarin with a…
Aug 31, 2026
Corporate Catalyst
Bullish
Impact 85
BioMarin Pharmaceutical shares are trading higher after the company announced it entered into binding terms with Ascendis Pharma.
This headline represents a significant corporate catalyst for BioMarin Pharmaceutical. Entering into binding terms with Ascendis Pharma suggests a strategic move, potentially invol…
Aug 31, 2026
Corporate Catalyst
Bullish
Impact 65
Reported Earlier, BioMarin Settles Global Yuviwel Dispute, Secures Up To 20% Sales Royalty
BioMarin Pharmaceutical Inc. announced a binding agreement with Ascendis Pharma A/S to resolve all global patent and ancillary disputes concerning Ascendis's drug, Yuviwel. This se…
Aug 19, 2026
Corporate Catalyst
Neutral
Impact 55
BMO Capital Initiates Coverage On BioMarin Pharmaceutical with Outperform Rating, Announces Price Target of $98
BMO Capital's initiation of coverage on BioMarin Pharmaceutical (BMRN) with an 'Outperform' rating and a $98 price target signals a positive outlook from a significant financial in…
Aug 18, 2026
Corporate Catalyst
Bullish
Impact 85
BioMarin Seeks to Strengthen Market Position in Rare Bone Disease Treatment
BioMarin's acquisition of Alesta Therapeutics is a strategic move to expand its rare disease portfolio with ALE1, an oral therapy for hypophosphatasia (HPP). This is significant be…
Aug 18, 2026
Corporate Catalyst
Bullish
Impact 92
BioMarin Pharmaceutical Signs Agreement To Acquire Alesta Therapeutics For $275M
BioMarin Pharmaceutical is acquiring Alesta Therapeutics for an upfront payment of $275 million, with additional milestone payments up to $215 million. This transaction is signific…
Aug 17, 2026
Corporate Catalyst
Bullish
Impact 55
Piper Sandler Maintains Overweight on BioMarin Pharmaceutical, Raises Price Target to $88
Piper Sandler analyst Allison Bratzel maintained an 'Overweight' rating on BioMarin Pharmaceutical and raised the price target from $82 to $88. This action signals increased confid…
Aug 17, 2026
Corporate Catalyst
Bullish
Impact 55
Barclays Maintains Overweight on BioMarin Pharmaceutical, Raises Price Target to $111
Barclays analyst Eliana Merle maintained an 'Overweight' rating on BioMarin Pharmaceutical (BMRN) and raised the price target from $105 to $111. This action signals continued bulli…
Aug 10, 2026
Corporate Catalyst
Bullish
Impact 65
BioMarin Pharmaceutical shares are trading higher after Canaccord Genuity maintained its Buy rating on the stock and raised its price target from $111 to $114.
This headline represents a positive corporate catalyst for BioMarin Pharmaceutical. Analyst upgrades and increased price targets often signal to the market that a company's fundame…
Aug 10, 2026
Corporate Catalyst
Bullish
Impact 75
BioMarin Pharmaceutical shares are trading higher after Canaccord Genuity maintained its Buy rating on the stock and raised its price target from $111 to $114.
The headline indicates a positive sentiment shift for BioMarin Pharmaceutical (BMRN) due to an analyst's reaffirmed 'Buy' rating and a modest price target increase. This type of co…
Aug 10, 2026
Corporate Catalyst
Bullish
Impact 55
Canaccord Genuity Maintains Buy on BioMarin Pharmaceutical, Raises Price Target to $114
Canaccord Genuity analyst Whitney Ijem has maintained a 'Buy' rating for BioMarin Pharmaceutical (BMRN) and raised the price target from $111 to $114. This action signals continued…
Aug 7, 2026
Corporate Catalyst
Bullish
Impact 55
Morgan Stanley Maintains Overweight on BioMarin Pharmaceutical, Raises Price Target to $124
Morgan Stanley analyst Matthew Harrison maintained an 'Overweight' rating on BioMarin Pharmaceutical (BMRN) and raised the price target from $119 to $124. This action signals conti…
Aug 7, 2026
Corporate Catalyst
Bullish
Impact 55
Oppenheimer Maintains Outperform on BioMarin Pharmaceutical, Raises Price Target to $97
Oppenheimer analyst Leland Gershell has maintained an 'Outperform' rating on BioMarin Pharmaceutical (BMRN) and slightly raised the price target from $95 to $97. This action reflec…
Aug 7, 2026
Corporate Catalyst
Bullish
Impact 85
BioMarin Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 guidance. Also, HC Wainwright & Co raised its price target on the stock from $50 to $60.
This headline represents a strong positive corporate catalyst for BioMarin Pharmaceuticals. Better-than-expected earnings and an increased long-term outlook directly impact investo…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 85
BioMarin Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 guidance.
This headline represents a significant positive corporate catalyst for BioMarin Pharmaceuticals. Better-than-expected earnings and, crucially, raised long-term guidance (FY26) indi…
Aug 6, 2026
Corporate Catalyst
Bearish
Impact 92
Biomarin Pharmaceutical Q2 Adj. EPS $1.20 Beats $0.69 Estimate, Sales $990.000M Beat $926.908M Estimate
Biomarin Pharmaceutical (BMRN) announced Q2 adjusted EPS of $1.20, significantly surpassing the $0.69 consensus estimate, and sales of $990 million, beating the $926.908 million es…
Jul 27, 2026
Corporate Catalyst
Bullish
Impact 65
BioMarin Pharmaceutical Enters Global Exclusive License Agreement And Collaboration With n-Lorem Foundation To Develop A First-In-Disease, Antisense Oligonucleotide Medicine For People Living With ReNU Syndrome
BioMarin Pharmaceutical has announced a collaboration with the n-Lorem Foundation to develop a first-in-disease ASO medicine for ReNU Syndrome, a newly discovered genetic condition…
Jul 16, 2026
Corporate Catalyst
Bullish
Impact 55
Citigroup Maintains Buy on BioMarin Pharmaceutical, Raises Price Target to $76
Citigroup analyst Eric Joseph maintained a 'Buy' rating on BioMarin Pharmaceutical (BMRN) and raised the price target from $75 to $76. This action signals continued analyst confide…
Jul 13, 2026
Corporate Catalyst
Bullish
Impact 75
MioMarin Pharmaceuticals Receives FDA Supplemental New Drug Application Approval For Vosoritide To Treat Pediatric Achondroplasia
MioMarin Pharmaceuticals (BMRN) announced that the FDA has granted full approval for its drug Vosoritide (VOXZOGO) for pediatric achondroplasia. This converts the prior accelerated…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.